Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Case report

Fecal microbiota transplantation for severe clostridium difficile infection after left ventricular assist device implantation: a case control study and concise review on the local and regional therapies

Authors: Zeina Z. Berro, Righab H. Hamdan, Israa H. Dandache, Mohamad N. Saab, Hussein H. Karnib, Mahmoud H. Younes

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

We report herein a case of fecal microbiota transplantation (FMT) used for severe Clostridium difficile infection for a 65-year-old Lebanese man who underwent left ventricular assist device implantation. To the best of our knowledge this is the first case report from Lebanon and the region presenting such technique.

Case presentation

The patient experienced diarrhea and rectal bleeding and was diagnosed of pseudomembranous colitis (PMC). His condition failed to improve on maximal pharmacological therapy. Protocolectomy, an invasive operation consisting in resection of the entire colon and rectum seemed to be the last resort before the patient responded to FMT given through gastroscopy.

Conclusion

Despite the increasing experience with FMT for C. difficile infection, published evidence in severe related cases from this region is very limited. Hence, we promote adjunctive FMT, an effective noninvasive method, to be considered as a promising early treatment option in severe C. difficile infection.
Literature
1.
El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis. 2012;44(3):228–30.CrossRefPubMed
2.
Le Monnier A, Zahar JR, Barbut F. Update on Clostridium difficile infections. Med Mal Infect. 2014;44(8):354–65.CrossRefPubMed
3.
Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol. 2013;19(43):7577–85.CrossRefPubMedPubMedCentral
4.
Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tull P, Gastmeier P, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect. 2008;14 Suppl 5:2–20.CrossRefPubMed
5.
Dinh A, Bouchand F, Le Monnier A. [Current treatment and epidemiology of Clostridium difficile infections]. Rev Med Interne. 2015;36(9):596–602.CrossRefPubMed
6.
Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.CrossRefPubMed
7.
Stabler RA, Dawson LF, Phua LT, Wren BW. Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. J Med Microbiol. 2008;57(Pt 6):771–5.CrossRefPubMed
8.
Gordon H, Harbord M. A patient with severe Crohn’s colitis responds to Faecal Microbiota Transplantation. J Crohns Colitis. 2014;8(3):256–7.CrossRefPubMed
9.
Trubiano JA, Gardiner B, Kwong JC, Ward P, Testro AG, Charles PG. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol. 2013;25(2):255–7.CrossRefPubMed
10.
Goudarzi M, Seyedjavadi SS, Goudarzi H, Mehdizadeh Aghdam E, Nazeri S. Clostridium difficile infection: epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica. 2014;2014:916826.CrossRefPubMedPubMedCentral
11.
Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRefPubMed
12.
Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical M, Infectious D. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 Suppl 2:1–26.CrossRefPubMed
13.
Xu MQ, Cao HL, Wang WQ, Wang S, Cao XC, Yan F, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol. 2015;21(1):102–11.CrossRefPubMedPubMedCentral
14.
Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946–53.CrossRefPubMed
15.
Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12 Suppl 1:S3–9.CrossRefPubMed
16.
Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854–9.PubMed
17.
Zainah H, Silverman A. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis. 2012;2012:810943.PubMedPubMedCentral
18.
Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics. 2010;126(1):e239–242.CrossRefPubMed
19.
Ray A, Smith R, Breaux J. Fecal microbiota transplantation for Clostridium difficile Infection: the Ochsner experience. Ochsner J. 2014;14(4):538–44.PubMedPubMedCentral
20.
Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2010;8(5):471–3.CrossRefPubMed
21.
Porter RJ, Fogg C. Faecal microbiota transplantation for Clostridium difficile infection in the United Kingdom. Clin Microbiol Infect. 2015;21(6):578–82.CrossRefPubMed
22.
Li Q, Wang C, Tang C, He Q, Zhao X, Li N, et al. Therapeutic modulation and reestablishment of the intestinal microbiota with fecal microbiota transplantation resolves sepsis and diarrhea in a patient. Am J Gastroenterol. 2014;109(11):1832–4.CrossRefPubMed
23.
Wang J, Xiao Y, Lin K, Song F, Ge T, Zhang T. Pediatric severe pseudomembranous enteritis treated with fecal microbiota transplantation in a 13-month-old infant. Biomed Rep. 2015;3(2):173–5.PubMedPubMedCentral
24.
Li Q, Wang C, Tang C, He Q, Zhao X, Li N, et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Crit Care. 2015;19(1):738.
25.
Gweon TG, Lee KJ, Kang DH, Park SS, Kim KH, Seong HJ, et al. A case of toxic megacolon caused by Clostridium difficile infection and treated with fecal microbiota transplantation. Gut Liver. 2015;9(2):247–50.CrossRefPubMedPubMedCentral
26.
Ehlermann P, Dosch AO, Katus HA. Donor fecal transfer for recurrent Clostridium difficile-associated diarrhea in heart transplantation. J Heart Lung Transplant. 2014;33(5):551–3.CrossRefPubMed
27.
Broecker F, Kube M, Klumpp J, Schuppler M, Biedermann L, Hecht J, et al. Analysis of the intestinal microbiome of a recovered Clostridium difficile patient after fecal transplantation. Digestion. 2013;88(4):243–51.PubMed
28.
Nagy GG, Varvolgyi C, Paragh G. [Successful treatment of life-threatening, treatment resistant Clostridium difficile infection associated pseudomembranous colitis with faecal transplantation]. Orv Hetil. 2012;153(52):2077–83.CrossRefPubMed
29.
Cammarota G, Ianiro G, Gasbarrini A, Masucci L, Sanguinetti M. Faecal transplantation for Clostridium difficile infection. Three cases treated in Italy. Dig Liver Dis. 2014;46(5):475.CrossRefPubMed
30.
Floe A, Leutscher P. Recurrent Clostridium difficile infection treated with faecal microbiota transplantation. Ugeskr Laeger. 2014;176(4):V04130223.
31.
Emanuelsson F, Claesson BE, Ljungstrom L, Tvede M, Ung KA. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis. 2014;46(2):89–97.CrossRefPubMed
32.
Garborg K, Waagsbo B, Stallemo A, Matre J, Sundoy A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis. 2010;42(11-12):857–61.CrossRefPubMed
33.
Dumitru IM, Dumitru E, Resul G, Curtali L, Paris S, Rugina S. Concomitant CMV and Clostridium difficile colitis in an immunocompetent patient treated with Ganciclovir and fecal transplantation. J Gastrointestin Liver Dis. 2014;23(2):221–2.PubMed
34.
Mattila E, Uusitalo-Seppala R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142(3):490–6.CrossRefPubMed
35.
Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37(1):42–7.CrossRefPubMed
36.
Polak P, Freibergerova M, Jurankova J, Kocourkova H, Mikesova L, Svacina R, et al. [First experiences with faecal bacteriotherapy in the treatment of relapsing pseudomembranous colitis due to Clostridium difficile]. Klin Mikrobiol Infekc Lek. 2011;17(6):214–7.PubMed
37.
Barbut F, Collignon A, Butel MJ, Bourlioux P. Fecal microbiota transplantation: review. Ann Pharm Fr. 2015;73(1):13–21.CrossRefPubMed
38.
Issa I, Moucari R. Probiotics for antibiotic-associated diarrhea: do we have a verdict? World J Gastroenterol. 2014;20(47):17788–95.PubMedPubMedCentral
39.
Kopterides P, Papageorgiou C, Antoniadou A, Papadomichelakis E, Tsangaris I, Dimopoulou I, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care. 2010;38(4):755–8.PubMed
40.
Arikan T, Unal A, Kocyigit I, Yurci A, Oymak O. Peritoneal dialysis-related peritonitis triggered by Clostridium difficile-associated colitis. Perit Dial Int. 2014;34(1):139–40.CrossRefPubMedPubMedCentral
41.
Goudarzi M, Goudarzi H, Alebouyeh M, Azimi Rad M, Shayegan Mehr FS, Zali MR, et al. Antimicrobial susceptibility of clostridium difficile clinical isolates in Iran. Iran Red Crescent Med J. 2013;15(8):704–11.CrossRefPubMedPubMedCentral
42.
Sadeghifard N, Salari MH, Ghassemi MR, Eshraghi S, Amin Harati F. The incidence of nosocomial toxigenic clostridium difficile associated diarrhea in Tehran tertiary medical centers. Acta Med Iran. 2010;48(5):320–5.PubMed
43.
Nasereddin LM, Bakri FG, Shehabi AA. Clostridium difficile infections among adult hospitalized patients. Am J Infect Control. 2009;37(10):864–6.
44.
Jamal WY, Mokaddas EM, Verghese TL, Rotimi VO. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents. 2002;20(4):270–4.CrossRefPubMed
45.
Al-Tawfiq JA, Momattin H, Al-Habboubi F, Dancer SJ. Restrictive reporting of selected antimicrobial susceptibilities influences clinical prescribing. J Infect Public Health. 2014;8(3):234–1. doi:10.​1016/​j.​jiph.​2014.​09.​004.
46.
Abdulaziz S, Abou-Shala N, Al-Tarifi A, Amin R. Salvage immunotherapy for fulminant pseudomembranous colitis. BMJ Case Rep. 2013, 2013.
47.
Brooks JP, Perry WB, Richards ML. Abdominal distention and diarrhea in a young female. Curr Surg. 2004;61(5):435–8.CrossRefPubMed
48.
Khan FY, Abu-Khattab M, Anand D, Baager K, Alaini A, Siddique MA, et al. Epidemiological features of Clostridium difficile infection among inpatients at Hamad General Hospital in the state of Qatar, 2006-2009. Travel Med Infect Dis. 2012;10(4):179–85.CrossRefPubMed
49.
Beloosesky Y, Grosman B, Marmelstein V, Grinblat J. Convulsions induced by metronidazole treatment for Clostridium difficile-associated disease in chronic renal failure. Am J Med Sci. 2000;319(5):338–9.CrossRefPubMed
50.
Martinelli M, Strisciuglio C, Veres G, Paerregaard A, Pavic AM, Aloi M, et al. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study. Inflamm Bowel Dis. 2014;20(12):2219–25.CrossRefPubMed
51.
Froom P. Commentary on “High frequency of nonadherence to Clostridium difficile treatment guidelines”. South Med J. 2014;107(9):600–1.CrossRefPubMed
52.
Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772–8.CrossRefPubMed
Metadata
Title
Fecal microbiota transplantation for severe clostridium difficile infection after left ventricular assist device implantation: a case control study and concise review on the local and regional therapies
Authors
Zeina Z. Berro
Righab H. Hamdan
Israa H. Dandache
Mohamad N. Saab
Hussein H. Karnib
Mahmoud H. Younes
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1571-6

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue

Research article

Pertussis in infants: an underestimated disease

Research article

Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil

Research article

Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam

Research article

Prevalence of hemorrhagic fever with renal syndrome in Yiyuan County, China, 2005–2014

Research article

Comparison of indoor contact time data in Zambia and Western Cape, South Africa suggests targeting of interventions to reduce Mycobacterium tuberculosis transmission should be informed by local data

Research article

Human tuberculosis caused by Mycobacterium bovis: a retrospective comparison with Mycobacterium tuberculosis in a Mexican tertiary care centre, 2000–2015

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits